CN103002898A - 作为C-MET抑制剂的6-(1-甲基-1 H-吡唑-4-基)-3-(2-甲基-2H-吲唑-5-基硫代)-[l,2,4]三唑并[4,3-B]哒嗪 - Google Patents

作为C-MET抑制剂的6-(1-甲基-1 H-吡唑-4-基)-3-(2-甲基-2H-吲唑-5-基硫代)-[l,2,4]三唑并[4,3-B]哒嗪 Download PDF

Info

Publication number
CN103002898A
CN103002898A CN2011800371928A CN201180037192A CN103002898A CN 103002898 A CN103002898 A CN 103002898A CN 2011800371928 A CN2011800371928 A CN 2011800371928A CN 201180037192 A CN201180037192 A CN 201180037192A CN 103002898 A CN103002898 A CN 103002898A
Authority
CN
China
Prior art keywords
compound
cancer
compounds
methyl
met
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800371928A
Other languages
English (en)
Chinese (zh)
Inventor
Z.吴
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN103002898A publication Critical patent/CN103002898A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN2011800371928A 2010-07-30 2011-07-22 作为C-MET抑制剂的6-(1-甲基-1 H-吡唑-4-基)-3-(2-甲基-2H-吲唑-5-基硫代)-[l,2,4]三唑并[4,3-B]哒嗪 Pending CN103002898A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36933510P 2010-07-30 2010-07-30
US61/369,335 2010-07-30
PCT/US2011/044926 WO2012015677A1 (en) 2010-07-30 2011-07-22 6- (1-methyl-1h-pyrazol-4-yl)-3-(2-methyl-2h-indazol-5-

Publications (1)

Publication Number Publication Date
CN103002898A true CN103002898A (zh) 2013-03-27

Family

ID=44513148

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800371928A Pending CN103002898A (zh) 2010-07-30 2011-07-22 作为C-MET抑制剂的6-(1-甲基-1 H-吡唑-4-基)-3-(2-甲基-2H-吲唑-5-基硫代)-[l,2,4]三唑并[4,3-B]哒嗪

Country Status (15)

Country Link
US (1) US8268836B2 (enExample)
EP (1) EP2598144B1 (enExample)
JP (1) JP5738412B2 (enExample)
KR (1) KR20130052740A (enExample)
CN (1) CN103002898A (enExample)
AR (1) AR085183A1 (enExample)
AU (1) AU2011282973B2 (enExample)
BR (1) BR112013002211A2 (enExample)
CA (1) CA2805494A1 (enExample)
EA (1) EA201270818A1 (enExample)
ES (1) ES2516940T3 (enExample)
IN (1) IN2012MN02924A (enExample)
MX (1) MX2013001247A (enExample)
TW (1) TWI431008B (enExample)
WO (1) WO2012015677A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104334581B (zh) * 2012-05-09 2018-02-02 伊莱利利公司 抗‑c‑Met抗体
CN103122000B (zh) * 2012-09-03 2013-12-25 中美冠科生物技术（太仓）有限公司 用作抗肿瘤药物的高选择性的c-Met激酶抑制剂
TWI667233B (zh) 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
US10386376B2 (en) 2015-11-09 2019-08-20 Jeimei, Llc Sample container with integrated test strip
CN106924260B (zh) * 2015-12-31 2018-05-25 北京浦润奥生物科技有限责任公司 化合物在制备用于治疗脑胶质瘤的药物中的用途
JP2022526713A (ja) 2019-03-21 2022-05-26 オンクセオ がんの処置のための、キナーゼ阻害剤と組み合わせたＤｂａｉｔ分子
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
TW202504611A (zh) 2023-03-30 2025-02-01 美商銳新醫藥公司 用於誘導ｒａｓ ｇｔｐ水解之組合物及其用途
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009056692A2 (fr) * 2007-08-09 2009-05-07 Sanofi-Aventis Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzimidazole, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met
CN101553490A (zh) * 2006-10-23 2009-10-07 Sgx药品公司 用作蛋白激酶调节剂的二环三唑类化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ568666A (en) * 2005-11-30 2011-09-30 Vertex Pharma [1,2,4]Triazolo[3,4-b][1,3,4]thiadiazole derivative as inhibitors of c-Met
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
PE20121506A1 (es) * 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
ES2393132T3 (es) 2006-10-23 2012-12-18 Sgx Pharmaceuticals, Inc. Moduoladores de proteína quinasa de triazolopiridazina
NZ575336A (en) 2006-10-23 2012-04-27 Sgx Pharmaceuticals Inc Bicyclic triazoles as protein kinase modulators
WO2009106577A1 (en) 2008-02-28 2009-09-03 Novartis Ag Imidazo [1,2-b] pyridazine derivatives for the treatment of c-met tyrosine kinase mediated disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101553490A (zh) * 2006-10-23 2009-10-07 Sgx药品公司 用作蛋白激酶调节剂的二环三唑类化合物
WO2009056692A2 (fr) * 2007-08-09 2009-05-07 Sanofi-Aventis Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzimidazole, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met

Also Published As

Publication number Publication date
KR20130052740A (ko) 2013-05-23
JP2013532687A (ja) 2013-08-19
AU2011282973A1 (en) 2013-01-10
EP2598144B1 (en) 2014-08-13
BR112013002211A2 (pt) 2016-05-24
IN2012MN02924A (enExample) 2015-06-12
AU2011282973B2 (en) 2014-03-20
ES2516940T3 (es) 2014-10-31
TWI431008B (zh) 2014-03-21
US20120028984A1 (en) 2012-02-02
EP2598144A1 (en) 2013-06-05
CA2805494A1 (en) 2012-02-02
MX2013001247A (es) 2013-03-18
JP5738412B2 (ja) 2015-06-24
TW201219393A (en) 2012-05-16
AR085183A1 (es) 2013-09-18
US8268836B2 (en) 2012-09-18
WO2012015677A1 (en) 2012-02-02
WO2012015677A9 (en) 2012-12-13
EA201270818A1 (ru) 2013-05-30

Similar Documents

Publication Publication Date Title
CN103002898A (zh) 作为C-MET抑制剂的6-(1-甲基-1 H-吡唑-4-基)-3-(2-甲基-2H-吲唑-5-基硫代)-[l,2,4]三唑并[4,3-B]哒嗪
EP2850082B1 (en) 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido(2,3-d)pyrimidin-6-yl)phenyl)urea as Raf kinase inhibitor for the treatment of cancer
EP1560829B1 (en) Pyrimido compounds having antiproliferative activity (ii)
CN109689641B (zh) 一种取代的2-氢-吡唑衍生物的晶型、盐型及其制备方法
CN112521390A (zh) 制备parp抑制剂、结晶形式的方法及其用途
CN107922354A (zh) 作为idh2抑制剂的杂环化合物
CN109641902B (zh) 可用作人pde1抑制剂的三唑并吡嗪酮衍生物
CN108329321A (zh) 一种新颖的吡唑并［3，4－d］嘧啶类JAK激酶抑制剂的制备与应用
CN112424202B (zh) 抑制cdk4/6活性化合物的晶型及其应用
CN114592061A (zh) 用于ttk抑制剂化疗的预后生物标记
CN110885331B (zh) 一种6-氨基-1H-吡唑并[3，4-d]嘧啶类JAK激酶抑制剂的制备与应用
EP3661936B1 (en) [1,2,4]triazolo[4,3-a]pyrazin-6(5h)-one derivatives
CN113527300A (zh) 布鲁顿酪氨酸蛋白激酶抑制剂
EP2800566B1 (en) Therapeutic use of imidazopyridine derivatives
JP7053654B2 (ja) ＰＩ３Ｋβ阻害剤としてのキノキサリン及びピリドピラジン誘導体
CN110078732A (zh) 嘌呤类化合物及其用途
HK40040143A (en) Process for preparing parp inhibitor, crystalline forms, and uses thereof
CN117582438A (zh) 吡啶类衍生物的药物组合物、制备方法及用途
HK40037648A (en) Crystal form of compound for inhibiting the activity of cdk4/6 and use thereof
HK40037648B (en) Crystal form of compound for inhibiting the activity of cdk4/6 and use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130327